Eli Lilly | LLY - Sales Revenues


Eli Lilly reported $24.4B in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Abbott USD 13.01B 423M Sep/2026
ALKERMES USD 480.13M 15.88M Sep/2026
Amgen USD 10.4B 300M Sep/2026
AstraZeneca USD 16.21B 830M Sep/2026
Baxter International USD 2.98B 20M Sep/2026
Biogen USD 2.8B 60M Sep/2026
Bristol-Myers Squibb USD 13.07B 100M Sep/2026
Coherus Biosciences USD 12.75M 1.18M Dec/2025
Drreddys Laboratories INR 86.71B 85.92B Sep/2026
Eli Lilly USD 24.4B 1.43B Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
Glaxosmithkline GBP 8.89B 1.2B Sep/2026
J&J USD 25.4B 89M Sep/2026
Medtronic USD 9.8B 0 Jun/2026
Merck USD 18.1B 1.5B Sep/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Novartis USD 14.52B 112M Sep/2026
Novartis USD 15.03B 1.92B Sep/2026
Novo Nordisk DKK 78.49B 18.33B Jun/2026
Perrigo USD 989M 31M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
Phibro Animal Health USD 373.91M 10.02M Dec/2025
Prestige Brands USD 265.71M 15.91M Jun/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Roche Holding CHF 30.36B 14.71B Jun/2026
Sanofi EUR 14.44B 2.49B Sep/2026
Sanofi EUR 12.3B 160M Jun/2026
United Therapeutics USD 832.5M 49.2M Sep/2026
Zoetis USD 2.4B 100M Sep/2026